Eco-dextrin peritoneal dialysis solution (trade name Extraneal) is a product independently developed by Baxter International Company. Since 1997 was introduced in Europe, it has been widely used in more than 80 countries around the world. As a reference standard of drugs and bioequivalence, it has entered the drug yellow book database of FDA.
Extraneal, licensed by Baxter Healthcare Corporation of the United States and licensed by Baxter A/S of Europe, was announced by the National Medical Products Administration of the United States on February 23 this year, and both of them were listed as reference preparations as non-imported original research drugs. Eco-dextrin peritoneal dialysis solution can keep the abdomen for a longer time and does not contain glucose, so it has multiple clinical advantages compared with traditional peritoneal dialysis solution. Especially for peritoneal dialysis patients with poor ultrafiltration and diabetes, the benefit is more obvious.
Ecodextrin peritoneal dialysis solution has been recommended by authoritative organizations at home and abroad (such as international peritoneal dialysis guidelines and China peritoneal dialysis standard operating procedures). Recently, icodextrin peritoneal dialysate was approved to be listed in China, which broke the lack of new peritoneal dialysate in China for 30 years and brought new treatment options for peritoneal dialysis patients in China. ?
Peritoneal dialysis, another treatment for patients;
Peritoneal dialysis (PD) is the use of peritoneum under the action of gravity, through the catheter into the patient's peritoneal cavity. Due to the concentration gradient difference between the two sides of peritoneum, the solute on the high concentration side moves (disperses) to the low concentration side. Through the continuous replacement of peritoneal dialysate, the metabolic products and toxic substances in the body can be eliminated and the imbalance of water and electrolyte can be corrected.
Peritoneal dialysis is one of the alternative treatments for patients with end-stage renal disease. With the development of technology, the incidence of treatment-related complications decreased significantly. The early survival rate of peritoneal dialysis patients is better, and the long-term survival rate is equivalent to that of hemodialysis, which is more cost-effective.
The diversity of peritoneal dialysis treatment modes can help peritoneal dialysis patients to achieve normal work and life, which has great social benefits for individuals, families and society. The introduction of icodextrin peritoneal dialysis solution provides more treatment options for peritoneal dialysis patients in China.